The Cleveland Clinic, which has just won the second place in the list of the best hospitals in the United States, recently announced the 10 most promising medical innovations in 2017. The selection team consisted of 100 top physicians and researchers in their field of research. After many discussions and offensive and defensive battles, the final 10 medical technologies were selected from 200 technical nominations. These technologies were not considered. The reputation of the developer is not marked with the product name, but is based solely on the degree of technological innovation, the potential to cure or extend life. Cardiac vascular stents save many people's lives, but as long as the current materials are placed in the human body, the vascular stents will remain in the body forever, which may block blood flow and cause thrombosis. Therefore, the ultimate goal of medical development is to allow the stent to be absorbed by the body after the task is completed. In July 2016, the first new heart stent that can be absorbed by the body is FDA-approved. The material of this stent is a soluble polymer. When the stent is placed in the body to dilate blood vessels, it will be absorbed by the body two years later. Although only one stent has been FDA-approved so far, more new cardiac stents will appear on the market in the near future and will result in an output value of up to $2 billion. Human papillomavirus (HPV) is the culprit of many diseases and cancers, and it has a particularly strong impact on women's health. Almost 99% of cervical cancer patients have HPV infection. In 2017, the scientific community will conduct an ambitious plan to develop “self-administered HPV testing†reagents that women can self-test and send samples back to the research facility to confirm infection with HPV. Cervical cancer prevention and treatment is one of the UN Millennium Development Projects. At present, many international organizations have promoted it globally. It is expected that this testing reagent can carry out large-scale inspection and follow-up prevention and treatment plans. For many years, physicians have relied on microscopes and camera equipment for surgery, but most of the time they still need to perform and judge some precise tasks with the naked eye, but how senior physicians have their physical limitations. In the past year, two of the most complex surgical procedures—ophthalmology and neuromedicine—have begun to experiment with new technologies. Instead of having to work hard for a long time in surgery, surgeons can lift their heads and build high resolution in the instrument. In 3D visual images, the operation is performed in a more comfortable and efficient manner. In addition, some software vendors are preparing to develop augmented reality glasses, which can display the hologram of the human anatomy. In addition to being used in surgery, it can also be used in teaching to help medical students familiar with the human body structure. Experimental data show that one-third of people with depression are refractory depression, and drug treatment cannot effectively improve the condition. Often such patients turn to electrotherapy or other more intense ways, even when all methods are exhausted, desperately settle their lives. In 2013, the otherwise infamous KTAMINE was developed to have the ability to inhibit neuronal N-methyl-D-aspartate (NMDA) receptors. In preliminary human trials, 70% of refractory melancholy The symptomatic improvement of symptoms within 24 hours after the injection of a low dose of K, is the first such strong and effective experimental result for refractory depression. Since then, K has reversed his position and is expected to bring a glimmer of hope to these severely depressed patients in 2017. In the era of big data, medical information is perhaps one of the most difficult areas to integrate, involving not only past cases, video photos, medical orders, but even insurance items and drug use. But in 2017, HL7 International will release a set of tools that can be used as “translation software†for two health insurance systems and develop their own communication language. The first version that is expected to be released will focus on clinical data integration, such as images or drugs, and the second version will integrate administrative statistics such as fees and demographics. In addition to the Fast Healthcare Interoperability Resources, startups and entrepreneurs can use this platform to build smart, massive data analysis technologies. Automated driving has become one of the most popular topics in 2016, but there are still many functions to be perfect before the real road, from collision warning to dozing alarms, etc., are the details that must be noticed by driving safety. It is expected that in 2017, there will be more discussion and research on these safety technologies, and it will involve health care, such as physiological reactions and nerve reflexes. Do you know the dream of an oncologist? I hope that one day I can avoid judging whether I am cancerous by subjective symptoms or tissue slices. Now their dreams will come true. Blood test (liquid biopsy) can detect DAN (circulaTIng tumor DNA, ctDNA) of tumor cells. After rupture of cancer cells, ctDNA releases cell debris and DNA into the blood circulation, so it can be directly obtained from blood. The DNA of tumor cells. Although relevant research is still going on, the research institute estimates that this revolutionary product will bring in annual sales of 10 billion US dollars, and many well-known pharmaceutical companies also invest resources to develop and seize the pie. About one-third of cancer patients have leukemia (blood cancer). Common treatments include chemotherapy, radioactivity or stem cell transplantation. Now there are other options - cell immunotherapy. Initial experiments have confirmed that patients can improve their survival rate, and even advanced patients have a chance to cure. This immunotherapy is CART (Chimeric anTIgen receptor T cell), which simply recombines the T cell gene and strengthens the function of T cells to directly identify and destroy tumor cells. In some studies, CART technology has shown a 90% remission rate for patients with acute lymphoblastic leukemia. It is expected that this treatment will be submitted to the FDA in 2017, and will also lead CRAT treatment research for other blood diseases. Diabetes is one of the common chronic diseases in modern people. The complications are even more difficult. According to statistics, half of the patients died of cardiovascular disease caused by diabetes. However, although there are many drugs for controlling blood sugar, they cannot Effectively prevent complications. In 2016, some new drugs appeared and significantly reduced mortality, with the results of the Empagliflozin and LiragluTIde combination treatments being excellent. Empagliflozin acts on the kidneys to improve cardiovascular disease, while LiragluTIde has comprehensive benefits for many organs. According to the latest news released in June this year, the combination of Empagliflozin and Liraglutide reduced the pre-diabetes prevalence from 85% to 34.8%. Experts estimate that in 2017, more new drug combinations and complications will be followed, and prescriptions for diabetes will change dramatically, and patients will receive better care. Intestinal bacteria are like the gold mine of the human body. Thousands of bacteria "have" in our intestines and work for us. The chemical substances they release, in addition to affecting our digestion, also affect the role of drugs and the development of diseases. No wonder some people call "the intestines are the second brain of the human body." In recent years, intestinal bacteria research has gradually become a hot field, and some gene companies have turned to the potential of this type of microorganisms and developed bacteria (probiotics) that are beneficial to the intestines to improve the balance of intestinal bacteria. With the release of the National Microbiome Initiative in May 2016 and the investment of $121 million in cross-disciplinary research grants, enterobacteria is the future of biomedical technology.
Introducing VOSOON, the premium electronic cigarette brand that offers high-quality products with a wide variety of types. Featuring the latest dual-mesh technology, VOSOON delivers a rich and satisfying vaping experience with its unique and beloved design. With abundant vapor production, VOSOON offers both disposable and replaceable pod systems at a reasonable price. Choose VOSOON for a premium vaping experience.
VOSOON Vape,VOSOON Disposable Vape,VOSOON Prefilled Pod Kit,Prefilled Disposable Vape,VOSOON E-cig TSVAPE Wholesale/OEM/ODM , https://www.tsvaping.com
April 29, 2023